Viking Therapeutics (VKTX) Competitors $32.91 -0.29 (-0.87%) Closing price 04:00 PM EasternExtended Trading$32.74 -0.17 (-0.53%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, GMAB, RDY, MRNA, QGEN, VTRS, ASND, VRNA, and BBIOShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Genmab A/S Dr. Reddy's Laboratories Moderna Qiagen Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Do analysts recommend VKTX or MDGL? Viking Therapeutics presently has a consensus target price of $86.92, suggesting a potential upside of 164.12%. Madrigal Pharmaceuticals has a consensus target price of $420.63, suggesting a potential upside of 42.88%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has more volatility and risk, VKTX or MDGL? Viking Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.05, suggesting that its stock price is 205% less volatile than the S&P 500. Do institutionals and insiders have more ownership in VKTX or MDGL? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is VKTX or MDGL more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -19.98% -19.38% Madrigal Pharmaceuticals -123.38%-50.54%-37.19% Does the media refer more to VKTX or MDGL? In the previous week, Viking Therapeutics had 31 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 43 mentions for Viking Therapeutics and 12 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.04 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 10 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, VKTX or MDGL? Viking Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.53-21.51Madrigal Pharmaceuticals$180.13M36.28-$465.89M-$18.05-16.31 SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.73B$3.02B$5.70B$9.56BDividend YieldN/A2.40%4.71%4.06%P/E Ratio-21.5121.0028.1919.94Price / SalesN/A331.85461.9396.03Price / CashN/A42.5736.3258.72Price / Book4.658.138.295.77Net Income-$109.96M-$55.06M$3.25B$259.21M7 Day Performance2.52%0.88%0.21%-0.80%1 Month Performance24.10%15.04%8.71%9.81%1 Year Performance-46.27%2.54%32.76%14.37% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.5377 of 5 stars$32.91-0.9%$86.92+164.1%-49.7%$3.73BN/A-21.5120Trending NewsEarnings ReportAnalyst RevisionGap UpMDGLMadrigal Pharmaceuticals4.2535 of 5 stars$330.50-1.1%$420.63+27.3%+3.4%$7.33B$180.13M-18.2990LLYEli Lilly and Company4.9797 of 5 stars$762.72-1.2%$1,012.56+32.8%+0.4%$722.75B$49.00B62.0547,000Trending NewsAnalyst UpgradeGap DownGMABGenmab A/S4.0326 of 5 stars$21.67-1.0%$37.80+74.5%-18.6%$13.91B$3.12B12.322,682News CoveragePositive NewsAnalyst UpgradeRDYDr. Reddy's Laboratories2.6616 of 5 stars$14.56+0.6%$16.95+16.4%-9.5%$12.14B$3.81B22.0227,811Earnings ReportMRNAModerna4.257 of 5 stars$30.91-1.1%$46.61+50.8%-72.2%$12.01B$3.24B-3.565,800Upcoming EarningsQGENQiagen3.6232 of 5 stars$48.13-0.5%$49.40+2.7%+19.4%$10.70B$1.98B120.655,765Positive NewsUpcoming EarningsAnalyst DowngradeVTRSViatris2.6181 of 5 stars$8.89+0.1%$10.40+17.1%-23.3%$10.44B$14.74B-2.8132,000ASNDAscendis Pharma A/S3.379 of 5 stars$168.19-1.0%$223.07+32.6%+22.7%$10.31B$393.54M-26.851,017News CoverageAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.7655 of 5 stars$104.93+0.0%$109.00+3.9%+362.3%$8.93B$42.28M-52.4630Positive NewsBBIOBridgeBio Pharma4.6257 of 5 stars$45.85-1.4%$61.50+34.1%+70.9%$8.74B$221.90M-13.03400News CoverageUpcoming EarningsAnalyst Downgrade Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Qiagen Competitors Viatris Competitors Ascendis Pharma A/S Competitors Verona Pharma PLC American Depositary Share Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
